MK-0431/ONO-5435 Phase III Clinical Trial -Rapid-acting Insulin Secretagogue Add-on Study in Patients with Type 2 Diabetes-
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Ono Pharmaceutical
- 08 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2012 New trial record